0000000000644427

AUTHOR

Elena Verzoni

showing 6 related works from this author

Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC)

2014

e15568 Background: With the exception of the Temsirolimus (Tem) registration trial, prRCC pts are grossly underrepresented in trials that have evaluated different therapeutic strategies. Methods: W...

OncologyCancer Researchmedicine.medical_specialtyPoor riskbusiness.industrymedicine.diseaseTemsirolimusLarge cohortSurgeryOncologyRenal cell carcinomaInternal medicinemedicinebusinessmedicine.drug
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

2015

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T an…

Blood Glucoselcsh:MedicineBlood Pressureurologic and male genital diseasesTriglycerideBody Mass IndexAntineoplastic Agentchemistry.chemical_compoundRetrospective StudieRenal cell carcinomalcsh:ScienceMultidisciplinaryKidney NeoplasmKidney NeoplasmsSurvival RateEverolimuCholesterolDisease ProgressionHumanmedicine.drugResearch ArticleAdultmedicine.medical_specialtyAdolescentUrologyBlood sugarAntineoplastic AgentsYoung AdultInternal medicinemedicineCarcinomaHumansEverolimusCarcinoma Renal CellTriglyceridesNeoplasm StagingRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)EverolimusCholesterolbusiness.industrylcsh:RCarcinomaRenal CellAdolescent; Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Carcinoma Renal Cell; Cholesterol; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Lipid Metabolism; Neoplasm Staging; Retrospective Studies; Survival Rate; Triglycerides; Young Adult; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Lipid metabolismBiomarkermedicine.diseaseLipid Metabolismrenal; carcinomaBlood pressureEndocrinologyAgricultural and Biological Sciences (all)chemistryPharmacodynamicslcsh:QbusinessBiomarkersPloS one
researchProduct

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

2019

Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy for metastatic disease were included. We analyzed overall survival (OS), progression-free survival (PFS) and time-to-strategy failure (TTSF) using Kaplan&ndash

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyrenal cell carcinomaCabozantinibPrognosiContext (language use)urologic and male genital diseaseslcsh:RC254-282ArticlePazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineProgression-free survivalCabozantinib; Nivolumab; Prognosis; Real-world data; Renal cell carcinoma; Targeted therapynivolumabreal-world databusiness.industrySunitinibRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyAxitinib030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisprognosisbusinessmedicine.drugCancers
researchProduct

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

2021

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolle…

MaleCancer ResearchTime Factors2435immunogenicity0302 clinical medicineRisk FactorsNeoplasmsvaccineClinical endpointImmunology and Allergyantibodiesantibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine1506Prospective Studies030212 general & internal medicineImmune Checkpoint InhibitorsRC254-282Clinical/Translational Cancer ImmunotherapyAged 80 and overIncidenceIncidence (epidemiology)virus diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedVaccinationTreatment OutcomeItalyOncologyInfluenza Vaccines030220 oncology & carcinogenesisMolecular MedicineFemaleimmunotherapyAdultmedicine.medical_specialtyInfluenza vaccineImmunologyVaccine EfficacyimmunizationRisk AssessmentYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineHumansLung cancerAdverse effectAgedPharmacologybusiness.industryCancermedicine.diseasevaccinationImmunizationbusinessneoplasm
researchProduct

Supplementary_Material_-_online_only – Supplemental material for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhi…

2020

Supplemental material, Supplementary_Material_-_online_only for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG by Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casad…

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct